BRENTUXIMAB VEDOTIN PLUS CHP AS FIRST‐LINE TREATMENT IN CD30 + PERIPHERAL T‐CELL LYMPHOMAS: REAL LIFE EXPERIENCE FROM A SINGLE INSTITUTION IN SPAIN | Publicación